Aptevo Therapeutics Inc. (APVO) Earnings History
Net Loss12 years of earnings data (2014–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Aptevo Therapeutics Inc. (APVO) Earnings Overview
As of June 29, 2026, Aptevo Therapeutics Inc. (APVO) reported trailing twelve-month net income of -$26M, reflecting +99.7% year-over-year growth. The company earned $-24.75 per diluted share over the past four quarters.
Looking at the long-term picture, APVO's historical earnings data spans multiple years. The company achieved its highest annual net income of $8M in fiscal 2022.
Aptevo Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MGTX (-$121M net income, -140.3% margin), IMVT (-$506M net income), TGTX ($462M net income, 72.6% margin), APVO has comparable earnings metrics. Compare APVO vs MGTX →
APVO Earnings vs Peers
Earnings metrics vs comparable public companies
APVO Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$26M | -7.6% | -$26M | $-87.27 | - | - |
| 2024 | -$24M | -38.6% | -$25M | $-31458.00 | - | - |
| 2023 | -$17M | -316.9% | -$29M | $-834044.00 | - | - |
| 2022 | $8M | +128.2% | -$29M | $921915.00 | 257.8% | -919.7% |
| 2021 | -$28M | -60.3% | -$21M | $-999999.00 | -231.5% | -174.1% |
| 2020 | -$18M | +60.3% | -$27M | $-999999.00 | -411.9% | -638.1% |
| 2019 | -$45M | +16.7% | -$41M | $-999999.00 | - | - |
| 2018 | -$54M | -870.0% | -$52M | $-999999.00 | -232.8% | -224.0% |
| 2017 | $7M | +106.2% | -$54M | $-999999.00 | 47.6% | -368.1% |
| 2016 | -$112M | -89.5% | -$127M | $-999999.00 | -308.5% | -348.4% |
| 2015 | -$59M | -16.0% | -$61M | $-999999.00 | -176.5% | -181.8% |
| 2014 | -$51M | - | -$51M | $-999999.00 | -112.0% | -112.8% |
Download Data
Export APVO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
APVO — Frequently Asked Questions
Quick answers to the most common questions about buying APVO stock.
What is APVO earnings per share (EPS)?
APVO trailing twelve-month (TTM) diluted EPS is $-24.75, reflecting +99.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2014 to 2025 is available in the table on this page.
What is Aptevo Therapeutics Inc.'s net income?
Aptevo Therapeutics Inc. (APVO) trailing twelve-month net income is $-26M as of 2025. Earnings grew +99.7% year-over-year.
Is APVO profitable?
APVO is not currently profitable on a TTM basis, reporting a net loss of $-26M. Net margin is N/A. Investors should monitor for a return to profitability.
What is APVO's earnings growth rate?
APVO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2014 to 2025.
What are APVO's profit margins?
Aptevo Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -234.6%.
Is APVO growing earnings?
Yes, APVO earnings are accelerating — EPS growth of +99.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-26M. Earnings momentum is strengthening.
What was APVO's best earnings year?
Aptevo Therapeutics Inc.'s highest annual net income on record is $8M, achieved in fiscal year 2022. Earnings history on this page spans 2014 to 2025 and includes all annual and quarterly figures.
What were APVO's earnings last quarter?
APVO's most recent reported quarter was Q1 2026. Net income was $-7M with diluted EPS of $-6.41. For a full breakdown of all quarters, see the quarterly earnings table on this page.